Ginwa Enterprise (Group) Inc.

XSSC:600080 Stock Report

Market Cap: CN¥2.8b

Ginwa Enterprise (Group) Valuation

Is 600080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 600080's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 600080's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600080?

Key metric: As 600080 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600080. This is calculated by dividing 600080's market cap by their current revenue.
What is 600080's PS Ratio?
PS Ratio4.9x
SalesCN¥581.53m
Market CapCN¥2.82b

Price to Sales Ratio vs Peers

How does 600080's PS Ratio compare to its peers?

The above table shows the PS ratio for 600080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
603811 Zhejiang Cheng Yi Pharmaceutical
3.6xn/aCN¥2.6b
000952 Hubei Guangji Pharmaceutical
3.4xn/aCN¥2.3b
301331 Enwei Pharmaceutical
3.2xn/aCN¥2.5b
002566 Jilin Jian Yisheng Pharmaceutical
3.5xn/aCN¥2.5b
600080 Ginwa Enterprise (Group)
4.9xn/aCN¥2.8b

Price-To-Sales vs Peers: 600080 is expensive based on its Price-To-Sales Ratio (4.9x) compared to the peer average (3.4x).


Price to Sales Ratio vs Industry

How does 600080's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.32b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$793.41m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$415.45m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
600080 4.9xIndustry Avg. 3.6xNo. of Companies33PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 600080 is expensive based on its Price-To-Sales Ratio (4.9x) compared to the CN Pharmaceuticals industry average (3.6x).


Price to Sales Ratio vs Fair Ratio

What is 600080's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600080 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600080's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies